Oppenheimer updates on Tandem Diabetes Care [Seeking Alpha]
Tandem Diabetes Care, Inc. (TNDM)
Last tandem diabetes care, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.tandemdiabetes.com
Company Research
Source: Seeking Alpha
Oppenheimer analyst Steven Lichtman updates on yesterday's FDA approval of the t:slim X2 insulin pump with Basal-IQ for Tandem Diabetes Care ( TNDM ). Approval timing is in line, though compatibility with Dexcom's new G6 sensor in the initial approval is upside to expectations; TNDM had assumed a staggered approval with G5 compatibility first, potentially followed shortly thereafter by iCGM designation/G6 compatibility, writes Lichtman. Earlier G6 approval bodes well for the initial launch later this summer, he adds. Oppenheimner has an Outperform rating and a 12-18 month price target of $24 on TNDM. Previously: FDA OKs Tandem's t:slim X2 insulin pump with hypoglycemia management feature; shars up 1% after hours (June 21) Click to subscribe to real-time analytics on TNDM Now read: Generic Acthar Could Put Mallinckrodt Out Of Its Misery »
Show less
Read more
Impact Snapshot
Event Time:
TNDM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNDM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNDM alerts
High impacting Tandem Diabetes Care, Inc. news events
Weekly update
A roundup of the hottest topics
TNDM
News
- TANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
- Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target raised by analysts at Stifel Nicolaus from $37.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Wearable Injectors Market size worth $ 21.48 Billion, Globally, by 2031 at 15.30% CAGR – Report By Verified Market Research® [Yahoo! Finance]Yahoo! Finance
- Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
TNDM
Earnings
- 2/21/24 - Miss
TNDM
Sec Filings
- 4/9/24 - Form ARS
- 4/9/24 - Form DEFA14A
- 4/9/24 - Form DEF
- TNDM's page on the SEC website